Day: March 26, 2026

us corporate news

The Dixie Group, Inc. (DXYN) Files Form 8-K Report for March 26, 2026 – Company Information, Address, and Stock Details

Minichart

March 26, 2026

The Dixie Group Reports Full Year 2025 Financial Results – I...

Continue Reading 0

us corporate news

Designer Brands Inc. Reports FY2025 Results: Improved Gross Margin, Strong Adjusted Operating Income, and 2026 Profitability Outlook

Minichart

March 26, 2026

Executive Summary Designer Brands Inc., a leading desig...

Continue Reading 0

us corporate news

The Dixie Group 2026 Investor Update: High-End Residential Sales Strategy, Market Position, and Growth Outlook

Minichart

March 26, 2026

The Dixie Group, Inc. Releases March 2026 Investor Presentat...

Continue Reading 0

us corporate news

Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment

Minichart

March 26, 2026

Tonix Pharmaceuticals Announces First Participant Dosed in P...

Continue Reading 0

us corporate news

Hyperion DeFi Reports 64% Revenue Growth and 87% Adjusted Gross Profit Surge in Q4 2025, Projects 4x Profit Increase for 2026

Minichart

March 26, 2026

Hyperion DeFi Q4/FY2025 Financial Report: Detailed Investor ...

Continue Reading 0

us corporate news

Lovesac Company Reports Fiscal 2026 Financial Results and Key Metrics in Latest SEC Filing

Minichart

March 26, 2026

The Lovesac Company Reports Q4 and Fiscal 2026 Results, Issu...

Continue Reading 0

us corporate news

NovoCure Limited Files 8-K Report Detailing Tumor Treating Fields Therapy and Corporate Information March 2026

Minichart

March 26, 2026

Key Highlights from the Filing Form Type: 8-K (Curre...

Continue Reading 0

us corporate news

The Lovesac Company Files 8-K: Common Stock (LOVE) Registered on NASDAQ, Stamford CT – March 26, 2026

Minichart

March 26, 2026

The Lovesac Company Announces Major Expansion of Share Repur...

Continue Reading 0

us corporate news

Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program

Minichart

March 26, 2026

Acumen Pharmaceuticals Reports 2025 Full-Year Financial Resu...

Continue Reading 0

us corporate news

Upstream Bio Announces Positive Phase 2 Results and Phase 3 Strategy for Verekitug in Severe Asthma and CRSwNP, Financials Support Operations Through 2027

Minichart

March 26, 2026

Upstream Bio Reports Q4 and FY2025 Results, Announces Phase ...

Continue Reading 0